GMAB
Price
$20.80
Change
-$0.42 (-1.98%)
Updated
Jan 17 closing price
Capitalization
13.38B
25 days until earnings call
TECH
Price
$75.83
Change
-$0.27 (-0.35%)
Updated
Jan 17 closing price
Capitalization
12.05B
17 days until earnings call
Ad is loading...

GMAB vs TECH

Header iconGMAB vs TECH Comparison
Open Charts GMAB vs TECHBanner chart's image
Genmab A/S ADS
Price$20.80
Change-$0.42 (-1.98%)
Volume$1.12M
Capitalization13.38B
Bio-Techne
Price$75.83
Change-$0.27 (-0.35%)
Volume$990.97K
Capitalization12.05B
GMAB vs TECH Comparison Chart
Loading...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GMAB vs. TECH commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMAB is a Hold and TECH is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (GMAB: $20.80 vs. TECH: $75.83)
Brand notoriety: GMAB and TECH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GMAB: 93% vs. TECH: 111%
Market capitalization -- GMAB: $13.38B vs. TECH: $12.05B
GMAB [@Biotechnology] is valued at $13.38B. TECH’s [@Biotechnology] market capitalization is $12.05B. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMAB’s FA Score shows that 0 FA rating(s) are green whileTECH’s FA Score has 2 green FA rating(s).

  • GMAB’s FA Score: 0 green, 5 red.
  • TECH’s FA Score: 2 green, 3 red.
According to our system of comparison, TECH is a better buy in the long-term than GMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMAB’s TA Score shows that 5 TA indicator(s) are bullish while TECH’s TA Score has 5 bullish TA indicator(s).

  • GMAB’s TA Score: 5 bullish, 4 bearish.
  • TECH’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, GMAB is a better buy in the short-term than TECH.

Price Growth

GMAB (@Biotechnology) experienced а -6.09% price change this week, while TECH (@Biotechnology) price change was +3.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.65%, and the average quarterly price growth was -1.89%.

Reported Earning Dates

GMAB is expected to report earnings on May 08, 2025.

TECH is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($13.4B) has a higher market cap than TECH($12B). TECH has higher P/E ratio than GMAB: TECH (79.82) vs GMAB (20.82). TECH YTD gains are higher at: 5.276 vs. GMAB (-0.335). GMAB has higher annual earnings (EBITDA): 6.97B vs. TECH (301M). GMAB has more cash in the bank: 17.3B vs. TECH (188M). TECH has less debt than GMAB: TECH (399M) vs GMAB (987M). GMAB has higher revenues than TECH: GMAB (19.8B) vs TECH (1.17B).
GMABTECHGMAB / TECH
Capitalization13.4B12B112%
EBITDA6.97B301M2,315%
Gain YTD-0.3355.276-6%
P/E Ratio20.8279.8226%
Revenue19.8B1.17B1,689%
Total Cash17.3B188M9,202%
Total Debt987M399M247%
FUNDAMENTALS RATINGS
GMAB vs TECH: Fundamental Ratings
GMAB
TECH
OUTLOOK RATING
1..100
1712
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
10069
SMR RATING
1..100
5678
PRICE GROWTH RATING
1..100
6149
P/E GROWTH RATING
1..100
8515
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECH's Valuation (3) in the Biotechnology industry is somewhat better than the same rating for GMAB (67) in the null industry. This means that TECH’s stock grew somewhat faster than GMAB’s over the last 12 months.

TECH's Profit vs Risk Rating (69) in the Biotechnology industry is in the same range as GMAB (100) in the null industry. This means that TECH’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's SMR Rating (56) in the null industry is in the same range as TECH (78) in the Biotechnology industry. This means that GMAB’s stock grew similarly to TECH’s over the last 12 months.

TECH's Price Growth Rating (49) in the Biotechnology industry is in the same range as GMAB (61) in the null industry. This means that TECH’s stock grew similarly to GMAB’s over the last 12 months.

TECH's P/E Growth Rating (15) in the Biotechnology industry is significantly better than the same rating for GMAB (85) in the null industry. This means that TECH’s stock grew significantly faster than GMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GMABTECH
RSI
ODDS (%)
Bearish Trend 5 days ago
56%
N/A
Stochastic
ODDS (%)
Bearish Trend 5 days ago
63%
Bearish Trend 5 days ago
73%
Momentum
ODDS (%)
Bullish Trend 5 days ago
63%
Bullish Trend 5 days ago
78%
MACD
ODDS (%)
Bullish Trend 5 days ago
61%
Bullish Trend 5 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
68%
Bullish Trend 5 days ago
70%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
70%
Bearish Trend 5 days ago
68%
Advances
ODDS (%)
Bullish Trend 11 days ago
64%
Bullish Trend 11 days ago
71%
Declines
ODDS (%)
Bearish Trend 5 days ago
68%
Bearish Trend 17 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
61%
Bearish Trend 5 days ago
73%
Aroon
ODDS (%)
N/A
Bullish Trend 5 days ago
60%
View a ticker or compare two or three
Ad is loading...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with CVAC. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then CVAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
-1.98%
CVAC - GMAB
39%
Loosely correlated
-1.91%
TECH - GMAB
35%
Loosely correlated
-0.35%
RIGL - GMAB
32%
Poorly correlated
+16.02%
INO - GMAB
32%
Poorly correlated
+8.90%
ARCT - GMAB
32%
Poorly correlated
-1.29%
More

TECH and

Correlation & Price change

A.I.dvisor indicates that over the last year, TECH has been loosely correlated with VIR. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if TECH jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TECH
1D Price
Change %
TECH100%
-0.35%
VIR - TECH
51%
Loosely correlated
+0.60%
BBIO - TECH
42%
Loosely correlated
-0.94%
MNKD - TECH
42%
Loosely correlated
N/A
CTMX - TECH
41%
Loosely correlated
-0.84%
VRDN - TECH
40%
Loosely correlated
+6.27%
More